- Question from Christine: Any news for those of us who are hormone- and HER2-positive?
- Answers - Andrew D. Seidman, M.D. Currently, there are two targeted therapies that have been shown to be effective in HER2-positive metastatic breast cancer: trastuzumab (brand name: Herceptin) and lapatinib (brand name: Tykerb). These agents are either given with chemotherapy, alone, or in combination with each other. There are many new agents that are emerging to target the HER2 pathway. At this ASCO meeting, we heard about a novel combination of two drugs, both being developed by Genentech. The combination of pertuzumab (brand name: Omnitarg) plus TDM-1 was shown to have significant anti-cancer activity among women with HER2 positive metastatic breast cancer that had progressed despite prior Herceptin and prior Tykerb. Pertuzumab is a monoclonal antibody that acts somewhat differently than Herceptin. TDM-1 is an antibody linked to a chemotherapy drug, a so-called immunoconjugate. One other promising class in development for HER2-positive metastatic breast cancer is called HSP-90 inhibitors. There are many reasons for patients to be optimistic that we will make real progress in the treatment of HER2-positive breast cancer in the near future.
On Thursday, June 10, 2010, our Ask-the-Expert Online Conference was called Updates from the 2010 ASCO Annual Meeting. Andrew Seidman, M.D. and Beth Baughman DuPree, M.D., F.A.C.S. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.